353 related articles for article (PubMed ID: 16342232)
1. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
[TBL] [Abstract][Full Text] [Related]
2. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
3. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
4. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
5. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
7. Four novel ULBP splice variants are ligands for human NKG2D.
Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
[TBL] [Abstract][Full Text] [Related]
8. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
Groh V; Smythe K; Dai Z; Spies T
Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
[TBL] [Abstract][Full Text] [Related]
9. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
10. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
[TBL] [Abstract][Full Text] [Related]
11. Cattle MIC is a ligand for the activating NK cell receptor NKG2D.
Guzman E; Birch JR; Ellis SA
Vet Immunol Immunopathol; 2010 Aug; 136(3-4):227-34. PubMed ID: 20399506
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.
Sáez-Borderías A; Gumá M; Angulo A; Bellosillo B; Pende D; López-Botet M
Eur J Immunol; 2006 Dec; 36(12):3198-206. PubMed ID: 17109473
[TBL] [Abstract][Full Text] [Related]
13. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
14. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
[TBL] [Abstract][Full Text] [Related]
15. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
16. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
Maccalli C; Nonaka D; Piris A; Pende D; Rivoltini L; Castelli C; Parmiani G
Clin Cancer Res; 2007 Dec; 13(24):7459-68. PubMed ID: 18094430
[TBL] [Abstract][Full Text] [Related]
17. UL16 binding proteins.
Cao W; He W
Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
[TBL] [Abstract][Full Text] [Related]
18. NKG2D and Related Immunoreceptors.
Strong RK; McFarland BJ
Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
[TBL] [Abstract][Full Text] [Related]
19. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
20. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]